D&D Updated Icon

How Soon is Now?

AI Ends the Wait for Better Health.


AI Just Broke the Discovery Timeline.

Until now, the path from promising target to lifesaving medicine has taken years. Cost and complexity keep better lives out of reach, while patients ask: how soon?

That timeline is now collapsing. Artificial intelligence, automation and advanced data systems are rewiring the paradigm of the biopharma discovery and development.

Human expertise drives the outcome. AI resets the tempo.

Now you can model and simulate biological systems in silico. Design and screen molecules digitally. Test entire hypotheses before the first experiment reaches the bench. Remove bottlenecks early and simulate and refine in hours what once took months.

AI just broke the discovery timeline.
For patients asking how soon, the answer is now.

D&D AI Visual

Discovery and Development Europe 2026

This is where the scientific community responds to that shift. Berlin. 15-16 June. 

Over 1,000 senior scientists, R&D leaders and technology innovators from pharma, biotech and AI-driven drug discovery platforms, across two co-located programmes and two full days of science, collaboration and possibility.

Drug Discovery Europe explores how AI, advanced biology and translational science are reshaping the earliest stages of the pipeline, from target identification and computational chemistry to targeted protein degradation, ADC development, lab automation and neuroscience drug development.

 Formulation and Delivery Europe takes the molecule forward, covering drug product design, delivery science, biologics formulation, RNA and oligonucleotide delivery, and the analytical development that gets candidates to clinic. 

Together they cover the full journey. From target to candidate. From candidate to medicine. Now.

Drug Discovery Square Image

Drug Discovery

Pushing traditional boundaries in pharmaceutical science by accelerating the discovery of novel therapeutics

F&D EU 2026 Square Image

Formulation & Delivery

Championing innovation within formulation and delivery by bringing together thought leaders who can advance complex, next generation drug formats to market

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers


The programme is built around the questions the field is actually asking in 2026.

Keynotes from Paul Workman OBE FRS of the Institute of Cancer Research, Dave Hallett of Recursion and Ingo Hartung of Merck Healthcare KGaA. Confirmed speakers from AstraZeneca, GSK, Sanofi, Novartis, Roche, Bayer, AbbVie, Novo Nordisk and Boehringer Ingelheim. 

Invite-only closed-door sessions for senior leaders on where smart capital is flowing, the real impact of AI on workflows, and the winning model for brain health innovation. An AI and Digitisation Zone bringing together the platforms reshaping how discovery works.

And 400 pre-arranged one-to-one meetings connecting the people who need to find each other.

Berlin. 15-16 June. The AI era of drug discovery begins here.

DDEU26 Keynote Supporting Image

Discovery & Development Europe 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration in Drug Discovery, Formulation and Delivery including: 

Drug Discovery & Automation Programme - Key Themes

Panel Discussion: Technological Advancements For Novel Target Discovery

  • Application of new technologies in identifying therapeutics for novel or currently undruggable targets
  • Utilising AI/ML
  • Challenges & future opportunities

 

Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

 

•    Optimising Hit discovery
•    Minimising false positives
•    Integration of techniques

 

Moderated by Jonathan Hopper, Vice President Platforms & Founder, OMass Therapeutics

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

 

  • Emerging technologies & techniques
  • Cross-sector partnership
  • Open innovation

 

Moderated by Alexander Natz, Secretary General, EUCOPE & panellists from Cicio Holdings, BioAge Labs, European Commission, Pfizer & Business Region Gothenburg

Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea

 

  • How research leaders identify and support fundable biotech innovations
  • Overcoming early-stage funding gaps in biotech startups
  • The role of research partnerships with pharma, VCs, and industry in startup success
  • What startups can learn from research-backed biotech wins

 


Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK 

Fireside Chat: Impact of AI & Big Data in Drug Discovery & Development

 

Panel Discussion: Translational Studies to Support Better Drug Design

  • Bridging the gap between pre-clinical & clinical research
  • Biomarkers & AI/ML in translational research

 

Moderated by Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research


•    Pharma, biotech & academic partnerships
•    The need for innovation, data & technology in CNS research
•    Challenges to be solved through collaboration 

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London


Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

  • Beyond blood-based biomarkers?
  • Are we any closer to a solution?
  • Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now? 


•    Impact of automation 
•    AI/ML  
•    Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Panellists include: James Love, Vice President Cross Modalities Workflows, Novo Nordisk, Sarah Trice, COO & Head of US Operations, XtalPi & Tom Kissling, pRED Lab Automation Partner, Roche

Day 2 Breakfast Workshop: SiLA & AnIML Splash


•    Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets 
•    Feel free to bring an instrument or your own data

Formulation and Delivery Programme - Key Themes

Panel Discussion: Moving Beyond Oral Delivery

 

•    Nanoparticles
•    Inhalation
•    Transdermal
•    Developments with Oral Delivery

Moderated by Sandor Batkai, Life Science Consultant, Former, Head of Medical Research and Intelligence, Cardior Pharmaceuticals

 

Panellists include:
• Moein Moghimi, Professor of Nanomedicine & Pharmaceutics, School of Pharmacy at Newcastle University 
• Kamalinder Singh, Professor of Pharmaceutical, Technology & Drug Delivery
• Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg

Panel Discussion: Developing New Biotherapeutic Modalities While Ensuring Robustness And Quality In Their Formulations

  • Improve the stability profile of biomolecules
  • New excipients
  • Impact on product quality and stability
  • Alternative ways of formulation

 

Moderated by Amardeep Bhalla, Executive Director, Regeneron

 

Panellists Include: 

• Ramesh Kashi, Former Senior Scientific Director, Bristol-Myers Squibb
• Tanvir Tabish, Director, Early Formulation Development, AstraZeneca
• Jack Palmer, Field Application Scientist, Advanced Instruments
• Martinus Capelle, Scientific Director, Head of Process & Delivery, Johnson & Johnson Innovative Medicine

Roundtable: Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where Are We Now?

  • Challenges of drug delivery across the BBB
  • Advances in nucleic acid brain therapies
  • Future technologies and translational strategies

 

Moderated by Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group and Moein Moghimi, Professor of Nanomedicine & Pharmaceutics, School of Pharmacy at Newcastle University

Key Event Highlights

An unmissable journey awaits you: from award winning speakers and insightful workshops, to an exclusive gala dinner. Discover the moments that will transform your Discovery & Development experience. 

The Start-up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs.

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

There are two options, based on the size of your organisation with prices starting from €1020. 

For further information and to get started submit the application form below.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

 

To be eligible for inclusion, you must meet the following criteria:

 

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding


What you will receive:

  • 1 full conference pass
  • 10-minute pitch on the Start-Up Stage
  • 1x1m space in Start-Up Zone for own partnering meetings; cocktail table provided, start-up to bring 1x pull-up banner
  • Logo featured on website & event platform as a participating start-up
  • Ability to arrange 1:1 meetings via the congress app

 

New Opportunities

Discovery & Development Young Scientist Awards

The Discovery & Development Young Scientist Poster Award recognises exceptional individual achievements in scientific research by PhD students, PostDocs, and early-career scientists.

The top three winners receiving the highest scores will be given a trophy, a £1,000 contribution towards travel costs, access to our LifeScienceXchange Pass, and the opportunity to present on the programme.

Three runner ups will be provided with the opportunity to present their work on the programme as well as access to the LifeScienceXchange Pass.

Included in the LifeScienceXchange Pass – 12 months access to expertly curated content, monthly thought leadership sessions & technology showcases.

NextGen Biomed - New Opportunities YSA

2026 Confirmed Speakers

Amardeep Singh Bhalla
Executive Director,
Regeneron
Andreas Bernkop-Schnürch
Professor,
Innsbruck University
Andreas Gryczke
ACoS Research Fellow,
AbbVie
Aurélie Thomas
Uk Head, Animal Science And Technology,
Astrazeneca
Douglas Ross Thriepland
Director Joint AstraZeneca-CRUK Functional Genomics Centre,
AstraZeneca
Emma Mead
CSO,
ARUK Oxford Drug Discovery Institute
Jean-Philippe Courade
Chief Scientific Officer,
discoveric bio alpha
Paul Workman OBE FRS
Harrap Professor of Pharmacology and Therapeutics,
The Institute of Cancer Research
Samir Mitragotri
Professor,
Harvard University
Sheila Peters
Executive Director and Early Asset Lead,
Boehringer Ingelheim
Sophie Janbon
Director,
AstraZeneca
Yogeshvar Kalia
Prof,
University of Geneva
Cristina Domã­nguez Hidalgo
Senior Automation Scientist,
AstraZeneca
Abhishek Choudhary
Principal Data Engineer,
Bayer
Aishwarya Parthasarathy
Associate,
Sofinnova Partners
Aldo Segura
Associate Director, Computational biology,
GSK
Ali Shirazi, Ph. D
Head of Smart Factory I AI, Automation, Robotics, Data & Digital I,
Sanofi
Amal Ali Elkordy
Professor,
University of Sunderland
Andreas Seidl
Chief Scientific Officer,
Formycon AG
Anselm Schneider
Head of Laboratory in Lead Discovery,
Nuvisan ICB GmbH
Arianna Sabò
Head of R&D,
QUANTRO Therapeutics GmbH
Aurélien Rizk
Co-Founder & Chief Scientific Officer,
InterAx Biotech
Avinash Murthy
Drug Product Lead,
Roche
Berna Kosekaya
Global Regulatory Policy Director,
AstraZeneca
Bilada Bilican
Senior Director,
Astrazeneca
Birgitta Leuthner
Scientific Director,
Merck Healthcare Kgaa
Carsten Spannhuth
Chief Scientific Officer,
ateka|tx
Cathy Vickers
Head of Innovation,
NC3Rs
Chris Hamlett
Director,
Astex Pharmaceuticals
Christian Pilger
Director,
AbbVie
Chuang Kee Ong
Director Data Product,
GSK
Covadonga Paneda
Chief Operating Officer,
Altamira Therapeutics
Cyril Teixeira da Silva
Investment Officer, Growth Finance & Venture Debt,
European Investment Bank
Dave Hallett
Chief Scientific Officer,
Recursion Pharmaceuticals
David Heinz
Digital Innovation Director,
SiLA
Dhwani Rana
Senior Scientist,
RCPE
Elena Fernandez-Kleinlein
Head of JLABS EMEA,
Johnson & Johnson
Elisabetta Leo
ED Global Asset Lead,
Ipsen
Emeric Nouailhac
Associate,
Wellington Partners
Emmanuelle Astoul
Head of Translation,
Wellcome Sanger Institute
Eric Munson
Professor,
Purdue University
Fabrizio Ricci
Senior Scientist,
Johnson & Johnson Innovative Medicine
Felix Hausch
Professor for Structure-Based Drug Research,
TU Darmstadt
Gisbert Schneider
Full Professor of Computer-Assisted Drug Design,
ETH Zürich
Gustavo Gutierrez
Director,
AstraZeneca
Ib Vestergaard
Senior Director,
Lundbeck
Ildiko Terebesi
Managing Director,
Invite Research
Ingo Hartung
Executive Director, Global Head of Medicinal Chemistry & Drug Design,
Merck & Cie KmG
Ingo Kober
Director,
Merck Healthcare KGaA
Ionel Mangalagiu
Professor,
Alexandru Ioan Cuza University Of Iasi
Jarrod Walsh
Director of Biochemical & Biophysical Screening,
AstraZeneca
Jean Ge
Patent Attorney,
Wolf Greenfield
Jenifer Mains
Director Formulation Science,
Bicycle Therapeutics
Jenny Karlsson
Senior Director - Targeted Radiopharmaceuticals,
Bayer
Jens Frauenfeld
Chief Executive Officer,
Salipro Biotech
Jitendra Kumar
Lead Scientist - Chemistry & Process Development,
Entos Pharmaceuticals
Johan Pihl
Chief Scientific Officer,
Cellectricon AB
Johannes Krupp
Research Program Director Neurology,
Servier
Jordan Bye
Senior Formulation Scientist,
Immunocore
Jordan Davies
Test,
Oxford Global
Jordan Lane
Cso & Co-founder,
Ignota Labs
Jorge Dias
Director Antibody Discovery,
Alchemab Therapeutics
Josh Bagley
Chief Scientific Officer,
a:head bio
Kamalinder Singh
Professor of Pharmaceutical Technology & Drug Delivery,
University of Central Lancashire
Kevin Gonzales
Principal Scientist,
Novo Nordisk
Kilian Huber
Associate Professor, Senior Group Leader Chemical Biology & Chemical Probes,
University of Oxford
Konstantinos Gkatzis
Ceo ,
Solyco Capital
Kristine Freude
Professor,
University Copenhagen
Krzysztof Brzózka
Chief Scientific Officer,
Ryvu Therapeutics
Laurent Gomez
Senior Vice President & Head of Discovery,
Iambic Therapeutics
Leena Otsomaa
VP, Head of Medicine Design,
Orion Corporation, Orion Pharma
Liam Good
Chief Scientific Officer,
Tecrea
Liuhong Chen
Vice President, Platform Innovation,
Bicycle Therapeutics
Lucas Bethge
VP, Group Leader Oligonucleotide Chemistry,
Silence Therapeutics
Magda Swedrowska
Associate Principal Scientist,
AstraZeneca
Magdalena Kierkowicz
Senior Scientist,
UCB
Magnus Ivarsson
Chief Scientific Officer,
astronautx.bio
Mahendra Deonarain
Chief Executive Officer,
Antikor Biopharma Ltd
Marc Siggel
Senior Scientist,
Merck KGaA
Mario Richter
Senior Director,
AbbVie
Mark Eccleston
CEO,
Valirx
Marta Koper
Senior Scientist,
UCB
Martin Kriebel
Group Leader,
NMI
Matthew Todd
Professor & Head of Global Research Collaborations,
University College London & Structural Genomics Consortium
Matthias Gehringer
Professor,
University of Tuebingen
Michael Johnson
Professor of Neurology & Genomic Medicine,
Imperial College London
Michael Koch
Lead High Throughput Biology,
Bayer
Min Shan
Associate Director of ADC Chemistry in MCDD, Discovery and Development Technologies, Merck Healthcare KGaA,
Merck Healthcare KGaA
Mitul Mehta
Professor,
King's College London
Moh Tsdayyon
Co-founder,
Apeikon Therapeutics
Mohammed Shahid Uddin
Senior Director ,
immunocore
Nathalie Meurice
Principal Research Scientist II,
AbbVie
Nazli Nezami
Senior Scientist,
Pfizer R&D UK
Nicola Chessum
Principal Scientist,
Boehringer Ingelheim
Peter Bitsch
Conjugation Specialist, Next Gen Drug Delivery,
Discovery Park ltd
Petrol Cal
Chief Operations Officer,
TargTex
Peyman Gifani
Founder & Chief Executive Officer,
AI VIVO
Philip Christophersen
Principal Scientist in Oral Formulation Research,
Novo Nordisk
Preben Bruun-Nyzell
Chief Executive Officer,
Neurometa Therapeutics
Rafal Kaminski
Chief Scientific Officer,
Angelini Pharma
Razvan Nutiu
Lead of Chemical Biology, High Content Imaging and Omics,
Bayer
Rekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Richard Hughes
VP - Technology, Information Security & Data,
Bicycle Therapeutics
Rick Ewing
VP, Head of Chemistry,
Rapafusyn
Robin Roehm
Chief Executive Officer,
Apheris AI GmbH
Roman Schulte-Sasse
Head of Data Science Discovery,
Aignostics GmbH
Ruth Shah
Head of Bayer Co.Lab Berlin,
Bayer
Sabrina Stöckl
Principal,
b2venture
Sai Jasti
Senior Vice President, Head of Data Science & AI,
Bayer
Sarah Ateaque
Manager, Scientific Solutions Consulting ,
Causaly
Senior Representative
,
Senior Representative
,
Shadi Farhangrazi
CEO,
S. M. Discovery Group (SMDG)
Simon Gilbert
Associate Director Bioscience,
Amphista Therapeutics Ltd
Søren Nielsen
Scientific Senior Director,
Amgen
Stefan Hauser
Group Leader,
DZNE (German Centre for Neurodegenerative Diseases)
Stefan Knapp
Professor of Pharmaceutical Chemistry,
Goethe University Frankfurt
Stefan Schiesser
Director of Medicinal Chemistry,
AstraZeneca
Steffen Renner
Associate Director Data Science,
Novartis
Steinunn Sara Helgudottir
Chief Scientific Officer,
Neurometa Therapeutics
Suruchi Vishwasrao
Senior Scientist,
Merck Life Science Pvt. Ltd.
Susanne Muller-Knapp
Chief Operating Officer,
The Structural Genomics Consortium
Valeriya Shunina
Investor,
Earlybird VC
Vijay Chandrasekar
Associate Principal Scientist,
AstraZeneca
Vijaya Lakshmi Kari
Group Leader,
Evotec
Vinay Pawar
Scientific Director (Data and AI), R&D External Innovation,
Novo Nordisk AS
Yann Gaston-Mathe
Chief Executive Officer,
Iktos AI
Yaroslav Nikolaev
Chief Technology Officer,
InterAx Biotech
Zameel Cader
Director, Oxford Headache Centre & Professor of Neuroscience & Neurology,
University of Oxford
Zoran Rankovic
Professor of Chemical Biology & Director, Centre for Protein Degradation,
The Institute of Cancer Research
f9d83b55-ff87-4538-a4e2-f67b63da4765-2-5668375logo-Axion-Logo_Tagline_2022

 

Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.


Regional Sales Director
AxionBio

5a563b71-261f-4b78-a13b-5b4890a6b41d-2-5668375logo-Copy-of-Arctoris-blue-logo-1-Transparent

 

Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development
Arctoris

Novalix Logo

 

The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.


Pharmacology Associate Director
Novalix

novartis-logo

 

This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.


Senior Principal Scientist

Novartis

Interested in Sponsoring NextGen Omics & Spatial Biology US 2025?

Become a driving force in accelerating the next generation of multi-omics-based treatments. NextGen Omics & Spatial Biology US offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of genomic medicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

D&D + LSX Combined Logo

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things Discovery & Development, direct to your inbox.

D&D Newsletter Icon-1

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

D&D + LSX Combined Logo

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things Discovery & Development, direct to your inbox.

D&D Newsletter Icon-1

Interested in Discovery & Development Europe 2026?